[go: up one dir, main page]

SMT202100237T1 - Anticorpi selettivi per protofibrille/oligomeri beta-amiloidi troncati n-terminali - Google Patents

Anticorpi selettivi per protofibrille/oligomeri beta-amiloidi troncati n-terminali

Info

Publication number
SMT202100237T1
SMT202100237T1 SM20210237T SMT202100237T SMT202100237T1 SM T202100237 T1 SMT202100237 T1 SM T202100237T1 SM 20210237 T SM20210237 T SM 20210237T SM T202100237 T SMT202100237 T SM T202100237T SM T202100237 T1 SMT202100237 T1 SM T202100237T1
Authority
SM
San Marino
Prior art keywords
terminaltruncated
protofibrils
amyloid
oligomers
antibodies selective
Prior art date
Application number
SM20210237T
Other languages
English (en)
Inventor
Lars Lannfelt
Pär GELLERFORS
Linda Söderberg
Karin Tegerstedt
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of SMT202100237T1 publication Critical patent/SMT202100237T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SM20210237T 2009-06-29 2010-06-29 Anticorpi selettivi per protofibrille/oligomeri beta-amiloidi troncati n-terminali SMT202100237T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22110509P 2009-06-29 2009-06-29
EP10739701.0A EP2448968B1 (en) 2009-06-29 2010-06-29 ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS
PCT/IB2010/052947 WO2011001366A1 (en) 2009-06-29 2010-06-29 N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease

Publications (1)

Publication Number Publication Date
SMT202100237T1 true SMT202100237T1 (it) 2021-05-07

Family

ID=42832352

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210237T SMT202100237T1 (it) 2009-06-29 2010-06-29 Anticorpi selettivi per protofibrille/oligomeri beta-amiloidi troncati n-terminali

Country Status (16)

Country Link
US (2) US20120100129A1 (it)
EP (2) EP2448968B1 (it)
JP (3) JP2012532094A (it)
AU (1) AU2010267640B2 (it)
CA (1) CA2765602C (it)
CY (1) CY1124034T1 (it)
DK (1) DK2448968T3 (it)
ES (1) ES2864049T3 (it)
HR (1) HRP20210611T1 (it)
HU (1) HUE053949T2 (it)
LT (1) LT2448968T (it)
PL (1) PL2448968T3 (it)
PT (1) PT2448968T (it)
SI (1) SI2448968T1 (it)
SM (1) SMT202100237T1 (it)
WO (1) WO2011001366A1 (it)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
NO347079B1 (no) 2006-03-23 2023-05-08 Bioarctic Neuroscience Ab Forbedrede protofibrilselektive antistoffer og anvendelse derav
CN102869680B (zh) 2010-02-26 2016-10-05 生命北极神经科学公司 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用
MX343873B (es) * 2011-03-16 2016-11-25 Probiodrug Ag Ensayo de diagnostico de anticuerpo.
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
CA2991856A1 (en) 2015-07-21 2017-01-26 Bioarctic Neuroscience Ab Method for treatment of traumatic brain injury targeting aggregated peptides
AU2017297804A1 (en) 2016-07-14 2019-01-24 Bioarctic Ab Brain delivery protein
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
KR20210039402A (ko) 2018-07-24 2021-04-09 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병의 치료 및 예방 방법
JPWO2021006212A1 (it) * 2019-07-08 2021-01-14
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
SI4172199T1 (sl) 2020-06-26 2025-08-29 Bioarctic Ab PROTITELESA, Kl SE VEŽEJO NA PROTOFIBRILE ALFA-SINUKLEINA
WO2023283650A1 (en) 2021-07-09 2023-01-12 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
WO2023034230A1 (en) 2021-08-30 2023-03-09 Eisai R&D Mangement Co., Ltd. Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
AU2022439338A1 (en) 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
TW202440628A (zh) 2022-12-22 2024-10-16 瑞典商生物極公司 新抗體

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
EP1571158B1 (en) * 1999-08-04 2009-10-14 University Of Southern California Globular assembly of amyloid beta protein and uses thereof
CA2414772C (en) * 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en) * 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
CA2561533C (en) * 2004-04-13 2015-06-16 Yvo Graus Anti-p-selectin antibodies
GB0413726D0 (en) * 2004-06-18 2004-07-21 Lauras As Compounds
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP2298807A3 (en) * 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
NO347079B1 (no) * 2006-03-23 2023-05-08 Bioarctic Neuroscience Ab Forbedrede protofibrilselektive antistoffer og anvendelse derav
AU2008322523B2 (en) * 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
HUE041223T2 (hu) * 2008-04-29 2019-05-28 Bioarctic Ab Antitestek és vakcinák alfa-szinukleinnel összefüggõ betegségek terápiás és diagnosztikai eljárásaiban történõ alkalmazásra

Also Published As

Publication number Publication date
SI2448968T1 (sl) 2021-07-30
JP2012532094A (ja) 2012-12-13
JP2017197531A (ja) 2017-11-02
WO2011001366A1 (en) 2011-01-06
CA2765602C (en) 2021-05-25
US20230295283A1 (en) 2023-09-21
AU2010267640B2 (en) 2015-03-05
EP2448968A1 (en) 2012-05-09
JP2019218362A (ja) 2019-12-26
EP2448968B1 (en) 2021-01-27
HUE053949T2 (hu) 2021-08-30
PL2448968T3 (pl) 2021-09-13
DK2448968T3 (da) 2021-04-12
CA2765602A1 (en) 2011-01-06
HRP20210611T1 (hr) 2021-05-28
ES2864049T3 (es) 2021-10-13
JP6884025B2 (ja) 2021-06-09
CY1124034T1 (el) 2022-05-27
US20120100129A1 (en) 2012-04-26
AU2010267640A1 (en) 2012-01-19
LT2448968T (lt) 2021-05-10
PT2448968T (pt) 2021-04-30
EP3892633A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
PL2448968T3 (pl) Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta
ZA201202299B (en) Method for decreasing immunigenicity
EP2391894A4 (en) SYSTEM IN RELATIVE TIME
GB0902476D0 (en) Method
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
ZA201106800B (en) Method for purifying recombinant fsh
GB0901444D0 (en) Method
HRP20150775T1 (en) Method for preparing hypoallergens
IL208514A0 (en) Process for preparing substituted biphenylanilides
GB0903316D0 (en) Method
IL217192A0 (en) Biorefinery method
ZA201203155B (en) Method for isolating methylglycinenitrile-n,n-diacetonitrile
PL2284468T3 (pl) Sposób suszenia zrębków
GB0902034D0 (en) Method
ZA201203445B (en) Method
GB0900560D0 (en) Method
EP2433942A4 (en) PROCESS FOR THE PREPARATION OF D-BIOTIN
GB0903026D0 (en) Novel method
GB0914318D0 (en) Method
GB2476082B (en) Improved base station architecture
IL199690A0 (en) Hanger for fhelf
GB0922292D0 (en) Novel Method
GB0919653D0 (en) Sutters for cars
GB0922677D0 (en) Nitrogen flush system